Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 3, May-June, p. 395–401

Publication type: original article

Language: English

Endothelin, Endothelial Cells, and von Willebrand Factor in Peripheral Blood of COPD in the Context of Hypoxemia

Endotelina, komórki śródbłonka oraz czynnik von Willebranda a hipoksemia u pacjentów z przewlekłą obturacyjną chorobą płuc

Maryla Krasnowska1,, Maryta Nittner−Marszalska1,, Ryszard Krasnowski1,, Wacław Kopeć1,, Andrzej Fal1,, Anna Białek1,

1 Department of Internal Medicine and Allergology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Background. The pulmonary endothelium plays a significant role in the pathobiology of chronic obstructive pulmonary disease (COPD), a chronic inflammatory disease of the respiratory tract in which increased activity or even damage to the endothelium due to chronic inflammation, hypoxemic stress, and/or angiogenesis may occur. The authors hypothesized that patients with COPD have increased concentrations of endothelin (ET−1) and von Willebrand factor (vWF) and/or circulating endothelial cell (CEC) counts, markers of endothelial activity and/or damage.
Objectives. The aim of the study was to assess the concentrations of ET−1 and vWF and the number of CECs in the peripheral blood of COPD patients compared with healthy individuals and to investigate if hypoxemia or ventilation disturbances affect these parameters.
Material and Methods. The study included 20 patients with COPD in stage III (according to GOLD) as well as 15 healthy individuals as controls. ET−1 and vWF were assessed by an immunoenzymatic method. Immunofluorescence using the specific monoclonal endothelium antibody CLB−HEC 19 MoAb was applied to evaluate CECs.
Results. The concentration of ET−1 was higher in COPD patients than in controls, medians being 1.2 (range: 1.0–3.8) and 0.44 (0.2–0.7) pg/ml (p < 0.001), respectively. The number of CECs was higher in COPD patients than in controls (mean: 1.5, range: 0.6–3.1 vs. mean: 0.44, range: 0.32–1.11 cells/ml, respectively, p < 0.001). The concentration of vWF in COPD patients did not differ from that in the controls. There was positive correlation between CEC count and the concentrations of both the studied factors (p < 0.05). The number of CECs in the patients peripheral blood correlated significantly with the pO2 value (Rs: 0.36, p < 0.05).
Conclusion. The increased number of CECs and concentration of ET−1 in peripheral blood may result from endothelial damage or activation occurring in COPD.

Streszczenie

Wprowadzenie. Wprzebiegu p.o.ch.p. dochodzi do aktywacji śródbłonka naczyniowego i uwolnienia jego mediatorów, m.in. endoteliny 1, a równocześnie destrukcji z powodu towarzyszącego chorobie przewlekłego niedotlenienia. Markerami uszkodzenia śródbłonka są: czynnik von Willebranda i krążące komórki śródbłonka (CEC).
Cel pracy. Ocena tych czynników w p.o.ch.p. w kontekście zaburzeń wentylacyjnych oraz hipoksemii.
Materiał i metody. Zbadano 20 pacjentów w III stadium p.o.ch.p. (według GOLD) oraz 15 osób zdrowych. ET−1 i vWF oznaczano we krwi metodą immunoenzymatyczną, CEC oceniano za pomocą metody immunofluorescencyjnej z wykorzystaniem swoistego przeciwciała monoklonalnego CLB−HEC 19. Wszyscy chorzy mieli oznaczane wskaźniki wentylacyjne płuc oraz mierzone gazy krwi arterializowanej włośniczkowej.
Wyniki. Stężenie ET−1 we krwi obwodowej było wyższe w grupie pacjentów z p.o.ch.p. niż u osób zdrowych, mediana (Me) wynosiła odpowiednio: Me = 1,2 (1,0–3,8) i Me = 0.44 (0,2–0,7); p < 0,001. Liczba krążących komórek śródbłonka była również większa w grupie pacjentów z p.o.ch.p.: Me = 1,5, (0,6–3,1) i Me = 0,44, (0,32–1,11); p < 0,001. Nie wykazano różnicy stężeń czynnika vWF między grupami. Stwierdzono korelację między wartością CECs i stężeniem obu pozostałych czynników (p < 0,05). Liczba CEC we krwi obwodowej korelowała z wartościami stężenia parcjalnego pO2 w arterializowanej krwi włośniczkowej (Rs = 0,36, p < 0,05).
Wnioski. Ocena krążących komórek śródbłonka i ET−1 w p.o.ch.p. może być jednym ze wskaźników uszkodzenia naczyń w tej chorobie.

Key words

COPD, endothelial cells, endothelin, vWF

Słowa kluczowe

p.o.ch.p., komórki śródbłonka naczyniowego, czynnik von Willebranda

References (22)

  1. National Institutes of Health, National Heart, Lung and Blood Institute/WHO: Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease. NHLBI/ WHO Workshop Report, Publication No 97−4051A, 1997.
  2. Jeffery P: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998, 9, 129–136.
  3. Sun G, Stacey MA, Bellini A, Marini M, Mattoli S: Endothelin 1 induces bronchial myofibroblast differentiation. Peptides 1997, 18, 1449–1451.
  4. Kizawa Y, Ohuchi N, Saito K, Kusama T, Murakami H: Effects of endothelin and nitric acid on proliferation of cultured guinea pig. Comp Biochem Physiol C Toxicol Pharmacol 2001, 128, 4, 495–501.
  5. Redington AE, Springall DR, Ghatei MA: Endothelin in bronchoalveolar lavage fluid and its relation to airflow obstruction in asthma. Am J Resp Crit Care Med 1995, 151, 1034–1039.
  6. Trakada G, Marangos M, Spiropoulos K: Mechanism of endothelin 1 elevation in chronic obstructive pulmonary disease patients with nocturnal oxyhemoglobin desaturation. Respiration 2001, 68, 134–139.
  7. Siemiątkowski A: von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury. Haemostasis 2000, 30, 189–195.
  8. Dignat−George F, Sampol J: Circulating endothelial cells in vascular disorders: New insights into an old concept. Eur J Haematol 2000, 65, 2150–2220.
  9. Murunga M, Fulton B, Bullock R: Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 2001, 163, 195–200.
  10. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997, 337(22), 1584–1590.
  11. Woywodt A, Schroeder M, Gwinner W, Mengel M, Jaegger M, Schwarz A, Haller H, Haubitz M: Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003, 76(1), 1–4.
  12. Woywodt A, Streiber F, Regelsberger H: Circulating endothelial cells as markers for ANCA−associated small vessel vasculitis. Lancet 2003, 306, 206–210.
  13. Sbarbati R, De Boer M, Marzilli M, Scarlattini M, Rossi G, van Mourik JA: Immunologic detection of endothelial cells in whole blood. Blood 1991, 77, 764–769.
  14. Van Mourik JA, Leeksma OC, Reinders J H de Groot PG, Zandbergen−Spaargaren J: Vascular endothelial cells synthesize a plasma membrane protein indistinguishable from the platelet membrane glycoprotein IIa. J Biol Chem 1985, 260, 11300–11306.
  15. Michiels C, Arnould T, Remacle J: Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. J Biochim Biophys Acta 2000, 1497, 1–10.
  16. Lopes AAB, Maeda NY, Goncalves RC et al.: Endothelial cells dysfunction correlates differentially with survival in primary and secondary hypertension. Am Heart J 2000, 139, 618–623.
  17. Hoshino M, Nakamura Y, Hamid QA: Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001, 107, 1034–1038.
  18. Mul F P, Zuurbier AE, Janssen H, Calafat J, van Wetering S, Hiemstra PS, Roos D, Hordijk PL: Sequential migration of neutrophils across monolayers of endothelial and epithelial cells. J Leukoc Biol 2000, 68, 529–537.
  19. Boussat S, Eddahibi S, Coste A, Fataccioli V, Gouge M, Housset B, Adnot S, Maitre B: Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000, 279, 371–378.
  20. Celik G, Karabiyikoglu G: Local and peripheral plasma endothelin 1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Respiration 1998, 65, 289–294.
  21. Chambers DC, Boldy DA, Ayres JG: Chronic respiratory symptoms, von Willebrand factor and longitudinal decline in FEV1. Resp Med 1999, 93, 726–733.
  22. Ferroni P, Basil S, Martini F et al.: Soluble P−selectin as a marker of platelet hyperreactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000, 48L, 21–27.
© Wroclaw Medical University